Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 1;109(8):djx124.
doi: 10.1093/jnci/djx124.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future

Affiliations
Review

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future

Karlyne M Reilly et al. J Natl Cancer Inst. .

Abstract

Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled "MPNST State of the Science: Outlining a Research Agenda for the Future" was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized.

PubMed Disclaimer

References

    1. Ferner RE, Gutmann DH.. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res .2002;625:1573–1577. - PubMed
    1. Kim A, Stewart DR, Reilly KM, et al.Malignant peripheral nerve sheath tumors state of the science: Leveraging clinical and biological insights into effective therapies [published online ahead of print May 16, 2017]. Sarcoma. 2017; doi: 10.1155/2017/7429697. - PMC - PubMed
    1. Miettinen M, Antonescu CR, Fletcher CD, et al.Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in neurofibromatosis 1 patients—a consensus overview [published online ahead of print May 24, 2017]. Hum Pathol .2017; doi: 10.1016/j.humpath.2017.05.010. - PMC - PubMed
    1. Morris SM, Acosta MT, Garg S, et al.Disease burden and symptom structure of autism in neurofibromatosis type 1: A study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry. 2016;7312:1276–1284. - PMC - PubMed
    1. Diggs-Andrews KA, Brown JA, Gianino SM, et al.Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol. 2014;752:309–316. - PMC - PubMed

Publication types

MeSH terms